# US 2008/0188444 A1 · Methods of treating various diseases using carnitine conjugates as dual prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188444 A1
- Document ID: US20080188444A1
- Status: Published application
- Kind: A1
- Application number: 11/980,846
- Filed: 2007-10-31
- Published: 2008-08-07
- Earliest claimed: 2003-11-12
- Assignees: SSV Therapeutics, Inc.
- Inventors: Om P. Goel
- Web page: https://patentgrep.com/patent/US20080188444A1

## CPC

- A61K 31/24: having an amino or nitro group
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/66: Phosphorus compounds
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07C 229/22: the carbon skeleton being further substituted by oxygen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention discloses uses for treating various diseases with novel dual prodrug compounds of Formula 1, wherein A is selected from the group consisting of a single bond, —O—, or —CH2—; m and n vary independently and are an integer from 1 to 15; p and q vary independently from 0 to 1; B is —CR3R4; D is selected from the group consisting of —CO2R5, —OR6, —OCOR7, —SO3R8, —SO2NH2, —OPO(OR9)(OR10), —OPO(OR9)(NH2), —OPO(OR9)—O—PO(OR10)(OR11), wherein R1 to R4 are independently selected from C1-C6 alkyl; and R5 to R11 are independently selected from the group consisting of hydrogen; C1-C6 alkyl; C3-C6 cycloalkyl; C2-C6 alkenyl; C6 alkynyl; C5-C10 aryl unsubstituted or substituted with C1-C6 alkyl, hydroxyl, C1-C6 alkoxyl, 1,3-dioxolanyl, cyano, halo, nitro, trihaloalkyl, carboxyl, C1-C6 acyl, C1-C6 hydroxyalkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 acylamino, C1-C6 alkoxylcarbonyl; C5-C6 arylalkyl unsubstituted or substituted with C1-C6 alkyl, hydroxyl, C1-C6 alkoxyl, 1,3-dioxolanyl, cyano, halo, trihaloalkyl, carboxyl, C1-C6 acyl, C1-C6 hydroxyalkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxylcarbonyl; C1-C6 carboxyalkyl; C1-C6 acylamino; C1-C6 sulfonatoalkyl; C1-C6 sulfamylalkyl; and C1-C6 phosphonatoalkyl. The various terms in Formula 1 are selected to optimize the physiochemical and biological properties such as, lipophilicity, bioavailability, and pharmacokinetics of compounds of Formula 1. There compounds are useful for the treatment of various metabolic, cardiovascular and neurological disorders.

## Claims

### Claim 1

A method of treating diseases comprising administering an effective amount of a dual prodrug compound or a pharmaceutically acceptable salt thereof of Formula 1,
wherein A is selected from the group consisting of a single bond, —O—, or —CH2—; m and n vary independently and are an integer from 1 to 15; p and q vary independently from 0 to 1; B is —CR3R4; D is selected from the group consisting of —CO2R5, —OR6, —OCOR7, —SO3R8, —SO2NH2, —OPO(OR9)(OR10), —OPO(OR9)(NH2), —OPO(OR9)—O—PO(OR10)(OR11),
wherein R1 to R4 are independently selected from C1-C6 alkyl; and
R5 to R11 are independently selected from the group consisting of hydrogen; C1-C6 alkyl; C3-C6 cycloalkyl; C2-C6 alkenyl; C6 alkynyl; C5-C10 aryl unsubstituted or substituted with C1-C6 alkyl, hydroxyl, C1-C6 alkoxyl, 1,3-dioxolanyl, cyano, halo, nitro, trihaloalkyl, carboxyl, C1-C6 acyl, C1-C6 hydroxyalkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 acylamino, C1-C6 alkoxylcarbonyl; C5-C6 arylalkyl unsubstituted or substituted with C1-C6 alkyl, hydroxyl, C1-C6 alkoxyl, 1,3-dioxolanyl, cyano, halo, trihaloalkyl, carboxyl, C1-C6 acyl, C1-C6 hydroxyalkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxylcarbonyl; C1-C6 carboxyalkyl; C1-C6 acylamino; C1-C6 sulfonatoalkyl; C1-C6 sulfamylalkyl; and C1-C6 phosphonatoalkyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein: A is a single bond, —O—, or —CH2—; m and n vary independently and are an integer from 1 to 6; p and q vary independently from 0 or 1; B is —CR3R4; D is selected from the group consisting of —CO2R5, —OR6, and
and R1 to R4 are independently selected from C1-C6 alkyl; and R5 and R6 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein: A is —O—; m is 4; n is 4; p is 0 or 1; q is 0 or 1; B is —CR3R4; D is selected from the group consisting of —CO2R5, —OR6, and
and R1 to R4 are methyl groups; R5 is hydrogen or an ethyl group; and R6 is hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein: A is —CH2—; B is —CR3R4; m is 4; n is 5; p is 0 or 1; q is 0 or 1; D is selected from the group consisting of —CO2R5, —OR6, and
and R1 to R4 are methyl groups; R5 is hydrogen or an ethyl group; and R6 is hydrogen.

### Claim 5 (depends on 1)

The method of claim 1, wherein said disease is hyperlipoproteinemia or hyperlipidemia, diabetes, metabolic diseases, obesity, inflammation.

### Claim 6 (depends on 1)

The method of claim 1, wherein said disease is renal anemia.

### Claim 7 (depends on 1)

The method of claim 1, wherein said disease is Alzheimer's disease.
